Clinical Trial Detail

NCT ID NCT03301896
Title Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

head and neck squamous cell carcinoma

melanoma

Therapies

LHC165 + Spartalizumab

LHC165

Age Groups: adult senior

No variant requirements are available.